Clinical trials: Rivaroxaban
Sickle Cell Disease, Central Venous Catheter Thrombosis
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
Research Question: In adult SCD patients with CVC, is it feasible and safe to conduct an adequately powered RCT to evaluate the use of rivaroxaban as thromboprophylaxis in this population? Study Design: The study is a vanguard…
- Conditions
- Sickle Cell Disease, Central Venous Catheter Thrombosis, Venous Thromboembolism
- Trial name
- THIS (NCT05033314)
- Testing
- Rivaroxaban 10 MG
- Where
- 3 sites in Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
Patients with active cancer are ~5-fold more likely to develop a venous thromboembolism (VTE) than those without. When VTE occurs, cancer patients carry an up to a 3-fold higher rate of thrombosis recurrence and ~twice the risk…
- Trial name
- OSCAR-US (NCT04979780)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Where
- United States
- Volunteers
- 3,708 people
- Sponsor
- Bayer
Atrial Fibrillation
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation.
- Trial name
- VALIANT-AF-T (NCT06953726)
- Testing
- Apixaban, Rivaroxaban
- Where
- 9 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- VA Office of Research and Development
Atrial Fibrillation, Stroke
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
- Conditions
- Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
- Trial name
- ARC (NCT01747746)
- Testing
- Rivaroxaban, Warfarin and Enoxaparin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Cook County Health
Pharmacokinetics
Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions
Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders.Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels.
- Trial name
- NCT02367027
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer
Aortic Stenosis, Aortic Regurgitation
Rivaroxaban or Aspirin for Biological Aortic Prosthesis
Aortic valve replacement with a biological prosthesis is the most common valve surgery performed with about 1000 operations performed in Denmark each year.
- Conditions
- Aortic Stenosis, Aortic Regurgitation, Thrombosis
- Trial name
- NCT02974920
- Testing
- Rivaroxaban 10 MG, Aspirin
- Where
- 4 sites in Denmark
- Volunteers
- 1,000 people
- Sponsor
- Christian Torp-Pedersen
Pediatric Venous Thromboembolism
Rivaroxaban in Pediatric Patients With DVT
Prospective interventional randomized controlled trial to assess safety and efficacy of rivaroxaban in pediatric patients with acute deep venous thrombosis.
- Trial name
- NCT07618988
- Testing
- Rivaroxaban, Enoxaparin, Heparin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 3 (NCT00361894)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 143 sites in Austria, Belgium and 17 more
- Volunteers
- 2,531 people
- Sponsor
- Bayer
Atrial Fibrillation
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling
Investigators are going to assess direct effect of SGLT2 inhibitors on left atrial remodeling in participants with nonvalvular paroxysmal atrial fibrillation regardless of diabetes status.
- Trial name
- NCT05993897
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Aswan University
STEMI - ST Elevation Myocardial Infarction
Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
To manage the ST-segment elevation myocardial infarction (STEMI) caused by plaque rupture, triggers platelet activation/aggregation and thrombin generation, requires dual (platelet and coagulation) pathway inhibition.
- Trial name
- NCT06013020
- Testing
- NOAC+DAPT, DAPT
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Zunyi Medical College
Venous Thromboembolism, Cancer
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
The purpose of this study is to show feasibility (efficacy and safety) of Rivaroxaban in the treatment of VTE in cancer patients in comparison to the standard treatment with low molecular weight heparin (LMWH).
- Trial name
- NCT02583191
- Testing
- Rivaroxaban, low-molecular heparine
- Where
- Germany
- Volunteers
- 246 people
- Sponsor
- AIO-Studien-gGmbH
Venous Thrombosis
Oral Rivaroxaban in Children With Venous Thrombosis
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. There will also be a check for bleeding and worsening of blood clots.
- Trial name
- EINSTEINJunior (NCT01684423)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
- Where
- 59 sites in United States, Australia and 8 more
- Volunteers
- 64 people
- Sponsor
- Bayer
Atrial Fibrillation
A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage
The primary purpose of this study is to evaluate the risk of major bleeding and stroke/systemic embolism (SE) among novel oral anti-coagulant (OAC) naïve and warfarin naïve Medicare Advantage patients with non-valvular atrial…
- Trial name
- NCT03189069
- Testing
- Apixaban, Dabigatran, Rivaroxaban
- Volunteers
- 36,000 people
- Sponsor
- Bristol-Myers Squibb
Vascular Calcification
Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients
This study examines patients on chronic hemodialysis with non-valvular atrial fibrillation, who have a CHA2DS2-VASc Score of ≥ 2 and therefore are candidates for or already receive a vitamin K antagonist.
- Trial name
- NCT02610933
- Testing
- rivaroxaban, Vitamin K2
- Where
- Belgium
- Volunteers
- 117 people
- Sponsor
- Onze Lieve Vrouw Hospital
Hypertrophic Cardiomyopathy (HCM)
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Hypertrophic cardiomyopathy (HCM) is a common (> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest.
- Trial name
- LA-HCM (NCT07202897)
- Testing
- Anticoagulant treatment Rivaroxaban, Best medical therapy
- Where
- 17 sites in France
- Volunteers
- 532 people
- Sponsor
- Rennes University Hospital
Atrial Fibrillation, Percutaneous Coronary Intervention
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT)…
- Trial name
- PIONEER AF-PCI (NCT01830543)
- Testing
- rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg
- Where
- 348 sites in United States, Argentina and 23 more
- Volunteers
- 2,124 people
- Sponsor
- Janssen Scientific Affairs, LLC
Acute Ischemic Stroke, Transient Ischemic Attack
Rivaroxaban Acute Stroke Safety Study
Atrial fibrillation is a common cardiac arrhythmia and a major risk for ischemic stroke. Furthermore the risk of stroke is higher in the first month after transient ischemic attack (TIA)/stroke.
- Trial name
- RASS (NCT02279940)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Alberta
Atrial Fibrillation
Oral Anticoagulation in Hemodialysis
The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients.
- Trial name
- NCT03799822
- Testing
- Rivaroxaban 10 MG Oral Tablet, MK-7 2000µg thrice weekly, Vitamin K Antagonist - Drug
- Where
- Belgium
- Volunteers
- 132 people
- Sponsor
- Onze Lieve Vrouw Hospital
Drug Drug Interaction Study
Rivaroxaban Sotorasib Interaction Study
Venous thromboembolic Events (VTEs) are common in lung cancer patients with an incidence of >15%, requiring anticoagulant treatment or prophylaxis.
- Trial name
- ROSIE (NCT06314763)
- Testing
- Rivaroxaban 20mg, Sotorasib 960mg
- Where
- Netherlands
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Gastric Bypass Status
Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery
The investigators are attempting to compare the anticoagulant (blood thinning) effects of a recently FDA approved medication, Rivaroxaban, in people who have undergone gastric bypass surgery to people who have not had this…
- Trial name
- NCT02058199
- Testing
- rivaroxaban
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University